

RNS Number : 2889I
EKF Diagnostics Holdings PLC
13 June 2011

**EKF Diagnostics Holdings plc
("EKF" or "the Company")**

Posting of Annual Report and Notice of AGM

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, confirms that the Annual Report and Accounts for the year ended 31 December 2010, the Notice of the Annual General Meeting and a Form of Proxy were posted to shareholders on 10 June 2011.

The Company's Annual General Meeting is to be held on Wednesday 6 July 2011 at the offices of Matrix Corporate Capital, One Vine Street, London W1J 0AH.

A copy of the annual report and accounts is available on the Company's website: www.ekfdiagnostics.com.

Enquiries:

EKF Diagnostics Holdings plc
David Evans, Executive Chairman
Julian Baines, CEO
Paul Foulger, FD

Mob: 07740 084452
Mob: 07788 420 859
Tel: 020 7823 1733

Zeus Capital (*Nominated Adviser and Joint Broker*)
Ross Andrews / Tom Rowley

Tel: 0161 831 1512

Matrix Corporate Capital LLP (*Joint Broker*)
Robert Naylor / Stephen Waterman / Jonathan Gosling

Tel: 020 3206 7000

Walbrook PR
Paul McManus

Tel: 020 7933 8780
Mob: 07980 541 893
paul.mcmanus@walbrookpr.com

Notes to the Editor:

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated two further acquisitions, Quotient Diagnostics Limited ("Quotient"), in October 2010, for a maximum total consideration of £5.41m and Argutus Medical Limited, in December 2010, for £2.18m.

The Group, with its head office in Cardiff and operations in London, Germany,

Poland, Russia and Ireland, is a leading diagnostics business, focused on the development, production and distribution of analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c. Recently, the Group has been granted SFDA approval in China for its Quo-Test HbA1c proprietary platform. With this approval, Quotient will be able to commence the promotion, distribution and sale of its Quo-Test HbA1c reagent kit on its proprietary platform in China.

This information is provided by RNS
The company news service from the London Stock Exchange

END

ACSSFSESEFFSELM admin Annual Financial Report 4290074 A Mon, 06/13/2011 - 07:00 Results and Trading Reports EKF